恒瑞医药：获瑞维鲁胺片的药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of Ruvelam tablets in combination with HS-20093 for prostate cancer treatment [1] Group 1: Clinical Trials - The company has been granted permission to conduct clinical trials for Ruvelam tablets in conjunction with HS-20093 for prostate cancer [1] - The approval signifies a potential advancement in the treatment options available for prostate cancer patients [1] Group 2: Product Development - Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, has its HRS-5965 capsules listed for priority review by the National Medical Products Administration [1] - The intended indication for HRS-5965 is for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitor therapy [1]